ReviewContemporary oncology (Poznan, Poland)2015
The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.
Review in Contemporary oncology (Poznan, Poland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2,540 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2,540 citing papers in PubMed.
- KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.Oncology letters · 2026Article
- T2T-CHM13 reference genome reduces mapping bias and enhances alignment accuracy at disease-associated variants.iScience · 2026Article
- High-resolution measurement of ERK activation state reveals determinants of BRAF regulation and drug sensitivity.bioRxiv : the preprint server for biology · 2026Article
- Investigating the role of CpG islands and DNA methylation at 3'UTRs in cancer.Life science alliance · 2026Article
- NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.Applied biochemistry and biotechnology · 2026Article
- Foundation model reveals the shared organization of transcription and topologically associating domains.Cell systems · 2026Article
- Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma.Discover oncology · 2026Article
- Adversarial random forests for omics synthesis.bioRxiv : the preprint server for biology · 2026Article
- A Pan-Cancer Analysis of microRNA Tissue Specificity and Its Association with Dysregulation.International journal of molecular sciences · 2026Article
- Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment.Journal of translational medicine · 2026Review
- Unveiling novel transcriptomic prognostic biomarkers for specific breast cancer subtypes and treatment regimens.Pharmacological reports : PR · 2026Article
- In-silico personalized protein-protein interaction networks prioritize candidate compounds for glioblastoma.PLoS computational biology · 2026Article
- Identification of CTHRC1 as a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma by Bioinformatics Analysis.Translational oncology · 2026Article
- GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction.Global medical genetics · 2026Article
- Multiomics, pharmacogenomic, and structural characterization of NCCRP1 as a candidate therapeutic target in ovarian cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- DSGCNLDA: A Multi-view Learning Model with DualScope Attention for lncRNA-Disease Association Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Structure-based identification of small-molecule stabilizers targeting mutant TP53 (Y220C) in breast cancer: a pharmacophore modeling, molecular docking and dynamics study.Journal, genetic engineering & biotechnology · 2026Article
- AET5: A transcriptome-guided molecular generation framework with contrastive self-supervised learning.PLoS computational biology · 2026Article
- Special Issue "Epigenetic Genes, Biomarkers and Immunotherapy in Cancers".International journal of molecular sciences · 2026Article
- The molecular similarity landscape of preclinical cancer models to patient tumors.JCI insight · 2026Article
2,480 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Cancer Genome Atlas (TCGA) is a public funded project that aims to catalogue and discover major cancer-causing genomic alterations to create a comprehensive "atlas" of cancer genomic profiles. So far, TCGA researchers have analysed large cohorts of over 30 human tumours through large-scale genome sequencing and integrated multi-dimensional analyses. Studies of individual cancer types, as well as comprehensive pan-cancer analyses have extended current knowledge of tumorigenesis. A major goal of the project was to provide publicly available datasets to help improve diagnostic methods, treatment standards, and finally to prevent cancer. This review discusses the current status of TCGA Research Network structure, purpose, and achievements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.